Publications
72
Citations
2,435
Est. group size
~3
Recurring co-author estimate
Active years
36
Publishing since 1991
This researcher's work spans medicinal chemistry and cancer biology, including the design of small-molecule drugs such as mitochondrial uncouplers for liver and metabolic disease, kinase inhibitors for hematologic cancers, and enzyme mechanism studies. Publications also touch on biomaterials (chitosan scaffolds for bone repair) and pharmaceutical analysis of drug degradation products, suggesting involvement in applied drug discovery and development pipelines, likely within an industry or translational research setting.
Publication output has fluctuated over the last decade, with a notable spike in 2023 (largely supplementary/data records) following a lull around 2020-2022, and a modest, uneven pace in more recent years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Chitosan scaffolds for bone applications: a detailed review of main types, features and multifaceted uses
European Cells and Materials · 2025
- Light regulation of flavin reduction by NAD(P)H: Activation of 2-haloacrylate hydratase
Archives of Biochemistry and Biophysics · 2024
- Light Regulation of Flavin Reduction by Nad(P)H: Activation of 2-Haloacrylate Hydratase
SSRN Electronic Journal · 2024
- Data from Efficacy of a Covalent ERK1/2 Inhibitor, CC-90003, in KRAS-Mutant Cancer Models Reveals Novel Mechanisms of Response and Resistance
2023
- <b>Liver-selective imidazolopyrazine mitochondrial uncoupler SHD865 reverses adiposity and glucose intolerance in mice</b>
2023
- <b>Liver-selective imidazolopyrazine mitochondrial uncoupler SHD865 reverses adiposity and glucose intolerance in mice</b>
2023
- Supplementary figure legends and supplementary methods from Efficacy of a Covalent ERK1/2 Inhibitor, CC-90003, in KRAS-Mutant Cancer Models Reveals Novel Mechanisms of Response and Resistance
2023
- Supplementary Tables and Figures from Efficacy of a Covalent ERK1/2 Inhibitor, CC-90003, in KRAS-Mutant Cancer Models Reveals Novel Mechanisms of Response and Resistance
2023
- Supplementary Tables and Figures from Efficacy of a Covalent ERK1/2 Inhibitor, CC-90003, in KRAS-Mutant Cancer Models Reveals Novel Mechanisms of Response and Resistance
2023
- Supplementary figure legends and supplementary methods from Efficacy of a Covalent ERK1/2 Inhibitor, CC-90003, in KRAS-Mutant Cancer Models Reveals Novel Mechanisms of Response and Resistance
2023
- Data from Efficacy of a Covalent ERK1/2 Inhibitor, CC-90003, in KRAS-Mutant Cancer Models Reveals Novel Mechanisms of Response and Resistance
2023
- Data from Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers
2023
- Data from Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers
2023
- Supplementary Figures 1 - 5, Tables 1 - 2 from Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers
2023
- Supplementary Figures 1 - 5, Tables 1 - 2 from Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers
2023
- Journal of Medicinal Chemistry×3
- ChemBioChem×3
- Angewandte Chemie International Edition×2
- PLoS ONE×2
- Biochemistry×2
- Michael H. Cardone
Medicine · The Ohio State University
- Min Xiao
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Julia Grace Reinke
Medicine · Indiana University
- Kathleen Kelly
Medicine · The Ohio State University
- Joyce Hardwick
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile